1. Home
  2. Stocks
  3. Gland Share Price
  • Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs

    • Gland Pharma Share Price

    Large Cap
    ₹1,845.6
    -19.85 (-1.06%)
    18 September, 2024 02:47 BSE: 543245 NSE: GLAND ISIN: INE068V01023

    Start SIP in Gland Pharma

    Start SIP

    Gland Pharma Performance

    Day Range

    • Low 1,831
    • High 1,874
    ₹ 1,845

    52 Week Range

    • Low 1,475
    • High 2,221
    ₹ 1,845
    • Open Price1,874
    • Previous Close1,865
    • Volume163275

    Gland Pharma Chart

    • Over 1 Month -5.11%
    • Over 3 Month -0.02%
    • Over 6 Month + 3.11%
    • Over 1 Year + 8.81%

    Gland Pharma Key Statistics

    P/E Ratio 42.1
    PEG Ratio -13.2
    Market Cap Cr
    Price to Book Ratio 3.5
    EPS 63.4
    Dividend 1.1
    Relative Strength Index 37.86
    Money Flow Index 42.09
    MACD Signal -22.58
    Average True Range 57.88

    Gland Pharma Investment Rating

    • Master Rating:

    • Gland Pharma has an operating revenue of Rs. 5,857.74 Cr. on a trailing 12-month basis. An annual revenue growth of 51% is outstanding, Pre-tax margin of 20% is great, ROE of 8% is fair but needs improvement. The company has a reasonable debt to equity of 1%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It has recently broken out of a base in its weekly chart but failed to keep its momentum and is trading around -12% from the pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 49 which is a POOR score indicating inconsistency in earnings, a RS Rating of 25 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C- which is evident from recent supply seen, Group Rank of 59 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Gland Pharma Financials
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 1,0121,1751,0981,011884785
    Operating Expenses Qtr Cr 718742728664625616
    Operating Profit Qtr Cr 294433369347259169
    Depreciation Qtr Cr 414340403938
    Interest Qtr Cr 151122
    Tax Qtr Cr 7711195906633
    Net Profit Qtr Cr 22332127725818879
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 4,3343,857
    Operating Expenses Annual Cr 2,7592,598
    Operating Profit Annual in Cr 1,4091,019
    Depreciation Cr 162147
    Interest Annual Cr 87
    Tax Annual Cr 362273
    Net Profit Annual Cr 1,043776
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 1,136368
    Cash from Investing Activity Annual Cr -2,9241,208
    Cash from Financing Annual Activity Cr -715
    Net Cash Flow Annual Cr -1,7951,591
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 8,9957,953
    Fixed Assets Annual Cr 1,8141,748
    Total Non Current Assets Annual Cr 4,9701,885
    Total Current Assets Annual Cr 4,5716,888
    Total Assets Annual Cr 9,5418,773
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 546483
    ROE Annual % 1210
    ROCE Annual % 1514
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 3835
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 1,4021,5371,5451,3731,209785
    Operating Expenses Qtr Cr 1,1371,1791,1891,049915617
    Operating Profit Qtr Cr 264359356324294168
    Depreciation Qtr Cr 9293105816538
    Interest Qtr Cr 6105652
    Tax Qtr Cr 7410691966732
    Net Profit Qtr Cr 14419219219419479
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 5,8353,865
    Operating Expenses Annual Cr 4,3322,600
    Operating Profit Annual in Cr 1,3331,025
    Depreciation Cr 345147
    Interest Annual Cr 267
    Tax Annual Cr 360274
    Net Profit Annual Cr 772781
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 997364
    Cash from Investing Activity Annual Cr -1,7571,208
    Cash from Financing Annual Activity Cr -79915
    Net Cash Flow Annual Cr -1,5601,587
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 8,7247,959
    Fixed Assets Annual Cr 3,9421,748
    Total Non Current Assets Annual Cr 5,0161,877
    Total Current Assets Annual Cr 5,6456,901
    Total Assets Annual Cr 10,6618,778
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 530483
    ROE Annual % 910
    ROCE Annual % 1314
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 2735
    Invest in Gland Pharma

    Gland Pharma Technicals

    EMA & SMA

    Current Price
    ₹1,845.6
    -19.85 (-1.06%)
    pointer
    • Bullish Moving Average
    • ___
    • 1
    • Bearish Moving Average
    • ___
    • 15
    • 20 Day
    • ₹1,895.30
    • 50 Day
    • ₹1,914.54
    • 100 Day
    • ₹1,894.55
    • 200 Day
    • ₹1,839.65
    • 20 Day
    • ₹1,878.94
    • 50 Day
    • ₹1,964.36
    • 100 Day
    • ₹1,882.98
    • 200 Day
    • ₹1,870.91

    Gland Pharma Resistance and Support

    PIVOT
    ₹1,850.12
    Resistance
    First Resistance 1,869.48
    Second Resistance 1,893.37
    Third Resistance 1,912.73
    RSI 37.86
    MFI 42.09
    MACD Single Line -22.58
    MACD -21.88
    Support
    First Support 1,826.23
    Second Support 1,806.87
    Third Supoort 1,782.98

    Gland Pharma Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 171,841 12,362,242 71.94
    Week 135,039 7,410,918 54.88
    1 Month 394,691 25,536,499 64.7
    6 Month 550,951 34,412,374 62.46

    Gland Pharma Result Highlights

    Gland Pharma Synopsis

    NSE-Medical-Generic Drugs

    Gland Pharma is involved in the business activities of Manufacture of other pharmaceutical and botanical products like hina powder etc.. Company’s Total Operating Revenue is Rs. 4167.43 Cr. and Equity Capital is Rs. 16.47 Cr. for the Year ended 31/03/2024. Gland Pharma Ltd. is a Public Limited Listed company incorporated on 20/03/1978 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24239TG1978PLC002276 and registration number is 002276.
    Market Cap 30,734
    Sales 4,295
    Shares in Float 7.91
    No of funds 184
    Yield 1.07
    Book Value 3.42
    U/D Vol ratio 0.7
    LTDebt / Equity
    Alpha -0.02
    Beta 0.56

    Gland Pharma Shareholding Pattern

    Owner NameJun-24Mar-24Dec-23Sep-23
    Promoters 51.83%57.86%57.86%57.86%
    Mutual Funds 30.53%23.01%21.34%19.79%
    Insurance Companies 1.29%1.21%1.8%1.79%
    Foreign Portfolio Investors 6.88%3.59%4.05%4.91%
    Financial Institutions/ Banks 0.01%
    Individual Investors 3.34%3.29%3.79%4.52%
    Others 6.13%11.04%11.16%11.12%

    Gland Pharma Management

    Name Designation
    Mr. Yiu Kwan Stanley Lau Chairman & Ind.Director
    Mr. Srinivas Sadu Managing Director & CEO
    Mr. Yao Fang Non Executive Director
    Dr. Jia Ai (Allen) Zhang Non Executive Director
    Mr. Qiyu Chen Non Executive Director
    Mr. Essaji Goolam Vahanvati Independent Director
    Mr. Udo Johannes Vetter Independent Director
    Mr. Satyanarayana Murthy Chavali Independent Director
    Ms. Naina Lal Kidwai Independent Director

    Gland Pharma Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Gland Pharma Corporate Action

    Date Purpose Remarks
    2024-08-06 Quarterly Results
    2024-05-22 Audited Results & Final Dividend
    2024-02-14 Quarterly Results
    2023-11-06 Quarterly Results
    2023-08-07 Quarterly Results
    Date Purpose Remarks
    2024-08-16 FINAL Rs.20.00 per share(2000%)Final Dividend

    Gland Pharma MF Shareholding

    Name Amount(cr)
    HDFC Mid-Cap Opportunities Fund Growth 75,382
    Nippon India Small Cap Fund - Growth 60,373
    ICICI Prudential Value Discovery Fund Growth 50,154
    Mirae Asset Large Cap Fund Regular Growth 41,593
    Mirae Asset Large & Midcap Fund Growth 40,205

    About Gland Pharma

    Gland Pharma is the leading company in creating some of the most beneficial injectable products that have significance in multiple therapeutic segments. In addition, the company is responsible for creating an online portfolio that allows users to buy their products online with a doctor's prescription. Right now, the company is manufacturing its products in seven different locations in India and which produce 750 million units with ease. The four major manufacturing facilities of the company have 22 production lines in order to provide finished formulations along with the Active Pharmaceutical Ingredient (API) Facilities as well. All the products that the company manufactures are delivered in the form of liquid vials, syringes that are pre-filled, ampoules, drops, and even bags as well. 

    In addition to this, the company is also putting a lot of effort into research for manufacturing and creating a delivery system that could hold complex injectables like peptides, suspensions, and long-lasting injectables. Apart from this, Gland Pharma Ltd is also putting its efforts into research and development of synthesizing some of the most complex molecules for the production of their injectables. Lastly, Gland Pharma Ltd is building the market of niche products in the pharmaceutical industry in India and throughout the world. 
     

    Products offered by Gland Pharma Ltd.

    • Anti Malarials
    • Anti-Infectives
    • Anti-Neoplastics
    • Blood Related
    • Cardiac
    • Gastro Intestinal
    • Gynaecological
    • Hormones
    • Neuro / Cns
    • Ophthal / Otologicals
    • Others
    • Pain / Analgesics
    • Respiratory
    • Vitamins / Minerals / Nutrients

     

    Gland Pharma Ltd is listed on 2 exchanges, and these are:

    • National Stock Exchange of India Ltd.
    • The Stock Exchange, Mumbai


    Included in Indices

    • NIFTY 50 - No 
    • NIFTY next 50 - YES
    • NIFTY 100 - YES
    • S&P BSE 200 - YES
    • S&P BSE 250 large midcap index- YES
    • S&P BSE finance- NO

    Other listing information

    • Incorporation date - March 20 1978
    • BSE group - A 
    • BSE Code - 543245
    • NSE - GLANDEQ

    1978
    PVN Raju establishes Gland Pharma to manufacture and market Heparin injection in the domestic market, as well as to provide contract manufacturing services to other pharmaceutical companies.

    1994
    From a private limited company, it becomes a public limited company.

    1996
    Becomes the first company to establish a PFS facility in India.

    2000
    Signs its first Contract Manufacturing agreement for regulated markets

    2007
    Enters the US market with Ketorolac PFS

    2013
    Entered European markets with Tirofiban
    The Visakhapatnam Oncology Formulations Facility has been approved by the USFDA.

    2016
    In 2016, the USFDA granted the first approval for a Penems plant in Hyderabad, as well as a Sterile Injectable plant in Pashamylaram, Hyderabad.
    First USFDA approval for an API plant in VSEZ and another in Pharmacity, Visakhapatnam.

    2017
    Fosun Pharma acquired a majority stake in the company.

    2018
    Enoxaparin injection received US market approval in 2018.
    The first ophthalmic product has been approved for sale in the United States.

    Gland Pharma FAQs

    What is Share Price of Gland Pharma ?

    Gland Pharma share price is ₹1,845 As on 18 September, 2024 | 02:33

    What is the Market Cap of Gland Pharma ?

    The Market Cap of Gland Pharma is ₹30406.6 Cr As on 18 September, 2024 | 02:33

    What is the P/E ratio of Gland Pharma ?

    The P/E ratio of Gland Pharma is 42.1 As on 18 September, 2024 | 02:33

    What is the PB ratio of Gland Pharma ?

    The PB ratio of Gland Pharma is 3.5 As on 18 September, 2024 | 02:33

    Is it a good time to invest in Gland Pharma Limited?

    Gland Pharma has an operating revenue of Rs.3,981.54 Cr. on a trailing 12-month basis. An annual revenue growth of 30% is outstanding, Pre-tax margin of 39% is great. Various broking houses and analysts recommend 'BUY' on the stock.

    What is the stock price CAGR of Gland Pharma Limited?

    The stock price CAGR of Gland Pharma Limited for 1 Year is 66%.

    Is Gland Pharma Limited debt-free?

    Gland Pharma Limited is debt-free and has a strong balance sheet enabling it to report stable earnings growth across business cycles.

    What is the ROE of Gland Pharma Limited?

    The ROE of Gland Pharma Limited is 16% is which good.

    Who is the Managing Director of Gland Pharma Limited?

    Mr. Srinivas Sadu is the Managing Director & Chief Executive Officer of Gland Pharma Limited.

    How to buy shares of Gland Pharma Ltd online?

    The company's shares can be bought online or offline by opening a Demat account with 5Paisa and verifying the KYC documents.

    What are some of the competitors of Gland Pharma Ltd?

    Given below is the list of companies that belong to the same industry or manufacture products of a similar niche as Gland Pharma Ltd. 

    • Cipla 
    • Sun Pharma 
    • Pfizer 
    • Lupin
    • Eris Life 
    • Aarti Drugs 
    • Hester Bio
    • RPG Life 
    • Bafna Pharma 
    • Jb Chemicals 

    Q2FY23
    Open Free Demat Account

    Be a part of 5paisa community - The first listed discount broker of India.

    +91
     
    footer_form

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 29/07/2024 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

    Email: support@5paisa.com

    Support Desk Helpline: 8976689766

    ©2024, 5Paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.